GLAXO2020-10-012020-12-31in-bse-fin:OneOperatingExpenses01Member GLAXO2020-10-012020-12-31in-bse-fin:FourOperatingExpenses01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares GLAXO 2020-04-01 2021-03-31 2021-01-07 INR Lakhs Third quarter Single segment Pharmaceuticals 2020-10-01 2020-12-31 Unaudited Standalone 8584200000.00 138700000.00 8722900000.00 683300000.00 2590200000.00 239000000.00 1592100000.00 9400000.00 177100000.00 1411700000.00 6702800000.00 2020100000.00 105300000.00 2125400000.00 612000000.00 -60100000.00 551900000.00 0.00 1573500000.00 0.00 0.00 0.00 0.00 1573500000.00 -47400000.00 1526100000.00 0.00 0.00 1694100000.00 10 9.29 9.29 0.00 0.00 9.29 9.29 Disclosure of Notes on financial results: n1. The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 5th February, 2021. n2. In accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, the Statutory Auditors have carried out a limited review of the standalone financial results for the quarter ended 31st December, 2020. n3. Exceptional items for the quarter ended 31st December, 2020 of Rs.1053 Lakhs comprise of reversal of provisions on account of product recall of Zinetac Rs.893 Lakhs, profit on sale of property Rs.184 Lakhs and other charges Rs.24 Lakhs. n nExceptional items for the quarter ended 31st December, 2019 of Rs.73690 Lakhs comprise financial impairment of Rs. 64031 Lacs connected to the under-utilisation of manufacturing facilities and Rs. 9659 Lacs on account of other related assets / cost, arising from strategic review consequent to decision to initiate a global voluntary recall (pharmacy/retail level) of ranitidine products including Zinetac in India. n4. Other income for the nine months period ended 31st December, 2020 and quarter ended 31st December, 2020 includes interest on Income tax refund of Rs.4902 Lacs (Nine months ended 31st December, 2019 and year ended 31st March, 2020: 1021 Lakhs) and Rs.634 Lacs (Quarter ended 31st December, 2019 : Rs.158 Lacs) respectively. n5. The Company has taken into account external and internal information for assesssing possible impact of COVID-19 on various elements of its financial results, including recoverability of its assets. n6. The Company has only one reportable segment which is Pharmaceuticals. Accordingly, no separate disclosures of segment information have been made. n7. Previous periods' figures have been re-grouped / re-classified wherever necessary. Single segment 2020-04-01 2020-12-31 Unaudited Standalone 23864600000.00 805800000.00 24670400000.00 3206600000.00 6543100000.00 10800000.00 4651400000.00 29000000.00 614300000.00 4191100000.00 19246300000.00 5424100000.00 -536000000.00 4888100000.00 1469200000.00 -29300000.00 1439900000.00 0.00 3448200000.00 0.00 0.00 0.00 0.00 3448200000.00 -77700000.00 3370500000.00 0.00 0.00 1694100000.00 10 20.35 20.35 0.00 0.00 20.35 20.35 Other Expenses 1411700000.00 Other Expenses 4191100000.00